As U.S. Life Sciences Market Recovers, “Definite Dichotomy” Among Companies
For months, executives in biopharma and other life sciences have been expressing optimism that in 2026, the industry will emerge from its post-COVID-19 doldrums. They have cited positive trends ranging from the rebound of the market for biotech stocks, to …